Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

Aghajanian, Carol

137 - Scientific Plenary
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

Tuesday, March 25, 2014: 7:47 AM

Ballroom B/C (Tampa Convention Center)

C. Aghajanian¹, B. A. Goff², L. R. Nycum³, Y. Wang⁴, A. Husain⁴ and S. V. Blank⁵
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²University of Washington Medical Center, Seattle, WA, ³Novant, Forsyth Regional Cancer Center, Winston-Salem, NC, ⁴Genentech, Inc., South San Francisco, CA, ⁵New York University School of Medicine, New York, NY

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

137 - Scientific Plenary
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

137 - Scientific Plenary Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer

137 - Scientific Plenary
Final analysis of overall survival in OCEANS, a randomized phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer